Brett P. Monia - 11 Jul 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Chief Executive Officer, Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Issuer symbol
IONS
Transactions as of
11 Jul 2025
Transactions value $
-$48,416
Form type
4
Filing time
15 Jul 2025, 20:54:09 UTC
Previous filing
23 Jun 2025
Next filing
01 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Monia Brett P Chief Executive Officer, Director 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia 14 Jul 2025 0001537529

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Sale -$48.4K -1.16K -0.64% $41.74 180K 11 Jul 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $41.79 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.